Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Familial Colorectal Cancer Type X.

Zetner DB, Bisgaard ML.

Curr Genomics. 2017 Aug;18(4):341-359. doi: 10.2174/1389202918666170307161643. Review.

PMID:
29081690
2.

Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer.

Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Tamura K, Almario JAN, Brant A, Borges M, Siddiqui A, Datta L, Wolfgang CL, Hruban RH, Klein AP, Goggins M.

Oncotarget. 2017 Feb 7;8(31):50824-50831. doi: 10.18632/oncotarget.15137. eCollection 2017 Aug 1.

3.

The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.

Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA.

Int J Mol Sci. 2017 Aug 31;18(9). pii: E1886. doi: 10.3390/ijms18091886. Review.

4.

Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.

Guan Z, Lan H, Chen X, Jiang X, Wang X, Jin K.

Mol Med Rep. 2017 Oct;16(4):4784-4790. doi: 10.3892/mmr.2017.7213. Epub 2017 Aug 10.

5.

Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.

Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M.

J Clin Oncol. 2017 Oct 20;35(30):3382-3390. doi: 10.1200/JCO.2017.72.3502. Epub 2017 Aug 2.

PMID:
28767289
6.

Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Au TH, Wang K, Stenehjem D, Garrido-Laguna I.

J Gastrointest Oncol. 2017 Jun;8(3):387-404. doi: 10.21037/jgo.2017.01.04. Review.

7.

MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress.

Bleuyard JY, Fournier M, Nakato R, Couturier AM, Katou Y, Ralf C, Hester SS, Dominguez D, Rhodes D, Humphrey TC, Shirahige K, Esashi F.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7671-7676. doi: 10.1073/pnas.1620208114. Epub 2017 Jul 3.

8.

Hereditary pancreatic cancer: related syndromes and clinical perspective.

Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G.

Hered Cancer Clin Pract. 2017 Jun 28;15:9. doi: 10.1186/s13053-017-0069-6. eCollection 2017. Review.

9.

Targeting reactive nitrogen species suppresses hereditary pancreatic cancer.

Li M, Chen Q, Ma T, Yu X.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7106-7111. doi: 10.1073/pnas.1702156114. Epub 2017 Jun 19. Erratum in: Proc Natl Acad Sci U S A. 2017 Jul 17;:.

10.

Familial Pancreatic Cancer and the Future of Directed Screening.

Welinsky S, Lucas AL.

Gut Liver. 2017 Nov 15;11(6):761-770. doi: 10.5009/gnl16414. Review.

11.

A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.

Melloni GEM, Mazzarella L, Bernard L, Bodini M, Russo A, Luzi L, Pelicci PG, Riva L.

Breast Cancer Res. 2017 May 31;19(1):63. doi: 10.1186/s13058-017-0854-1.

12.

Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer.

Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL.

Diabetes. 2017 May;66(5):1103-1110. doi: 10.2337/db16-1477.

13.

Gastrointestinal tract cancers: Genetics, heritability and germ line mutations.

Lv XP.

Oncol Lett. 2017 Mar;13(3):1499-1508. doi: 10.3892/ol.2017.5629. Epub 2017 Jan 20.

14.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

15.

Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.

Diwakarla C, Hannan K, Hein N, Yip D.

World J Gastroenterol. 2017 Apr 7;23(13):2276-2285. doi: 10.3748/wjg.v23.i13.2276. Review.

16.

Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.

Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP.

Int J Mol Sci. 2017 Apr 6;18(4). pii: E779. doi: 10.3390/ijms18040779. Review.

17.

Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.

Gravells P, Grant E, Smith KM, James DI, Bryant HE.

DNA Repair (Amst). 2017 Apr;52:81-91. doi: 10.1016/j.dnarep.2017.02.010. Epub 2017 Feb 17.

18.

Familial pancreatic cancer: Concept, management and issues.

Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T.

World J Gastroenterol. 2017 Feb 14;23(6):935-948. doi: 10.3748/wjg.v23.i6.935. Review.

19.

Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.

Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano A.

Int J Mol Sci. 2017 Jan 31;18(2). pii: E308. doi: 10.3390/ijms18020308. Review.

20.

A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.

Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S.

Am J Gastroenterol. 2017 Apr;112(4):537-554. doi: 10.1038/ajg.2016.610. Epub 2017 Jan 31. Review.

Supplemental Content

Support Center